Christine J. Saoud

Array ( [id] => 16511602 [patent_doc_number] => 20200390859 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => METHODS FOR TREATMENT OF BILE ACID-RELATED DISORDERS [patent_app_type] => utility [patent_app_number] => 16/917284 [patent_app_country] => US [patent_app_date] => 2020-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57541 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16917284 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17831476 [patent_doc_number] => 20220268780 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => METHODS OF PREDICTING ENDOMETRIAL RECEPTIVITY [patent_app_type] => utility [patent_app_number] => 17/622668 [patent_app_country] => US [patent_app_date] => 2020-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31088 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17622668 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17831476 [patent_doc_number] => 20220268780 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => METHODS OF PREDICTING ENDOMETRIAL RECEPTIVITY [patent_app_type] => utility [patent_app_number] => 17/622668 [patent_app_country] => US [patent_app_date] => 2020-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31088 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17622668 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16343617 [patent_doc_number] => 20200308267 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => VEGF-BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 16/903888 [patent_app_country] => US [patent_app_date] => 2020-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24866 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16903888 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17982629 [patent_doc_number] => 20220348665 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => BISPECIFIC ANTIBODY AGAINST Alpha-SYN/IGF1R AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/616799 [patent_app_country] => US [patent_app_date] => 2020-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28139 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 199 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616799 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17982629 [patent_doc_number] => 20220348665 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => BISPECIFIC ANTIBODY AGAINST Alpha-SYN/IGF1R AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/616799 [patent_app_country] => US [patent_app_date] => 2020-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28139 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 199 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616799 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17982629 [patent_doc_number] => 20220348665 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => BISPECIFIC ANTIBODY AGAINST Alpha-SYN/IGF1R AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/616799 [patent_app_country] => US [patent_app_date] => 2020-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28139 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 199 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616799 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17982629 [patent_doc_number] => 20220348665 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => BISPECIFIC ANTIBODY AGAINST Alpha-SYN/IGF1R AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/616799 [patent_app_country] => US [patent_app_date] => 2020-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28139 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 199 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616799 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17748234 [patent_doc_number] => 20220226437 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => Fibroblast growth factor 2 (FGF2) for Treatment of Human Sensorineural Hearing Loss [patent_app_type] => utility [patent_app_number] => 17/614845 [patent_app_country] => US [patent_app_date] => 2020-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8005 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17614845 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17748234 [patent_doc_number] => 20220226437 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => Fibroblast growth factor 2 (FGF2) for Treatment of Human Sensorineural Hearing Loss [patent_app_type] => utility [patent_app_number] => 17/614845 [patent_app_country] => US [patent_app_date] => 2020-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8005 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17614845 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17858572 [patent_doc_number] => 11439710 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-13 [patent_title] => Nucleic acids encoding modified relaxin polypeptides [patent_app_type] => utility [patent_app_number] => 16/885631 [patent_app_country] => US [patent_app_date] => 2020-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 43 [patent_no_of_words] => 94934 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16885631 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16451059 [patent_doc_number] => 20200360485 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES [patent_app_type] => utility [patent_app_number] => 16/884639 [patent_app_country] => US [patent_app_date] => 2020-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 112799 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16884639 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16628745 [patent_doc_number] => 20210047398 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-18 [patent_title] => ASPROSIN, A FAST-INDUCED GLUCOGENIC PROTEIN HORMONE [patent_app_type] => utility [patent_app_number] => 16/867183 [patent_app_country] => US [patent_app_date] => 2020-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44234 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16867183 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17850564 [patent_doc_number] => 20220280605 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => A Composition And Method For Improving The Profile Of Blood [patent_app_type] => utility [patent_app_number] => 17/607989 [patent_app_country] => US [patent_app_date] => 2020-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3851 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17607989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16238278 [patent_doc_number] => 20200255512 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => DUAL SPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/860891 [patent_app_country] => US [patent_app_date] => 2020-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18850 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -59 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16860891 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16343636 [patent_doc_number] => 20200308286 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => METHODS, COMPOSITIONS, AND KITS FOR TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/859006 [patent_app_country] => US [patent_app_date] => 2020-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7015 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16859006 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16359417 [patent_doc_number] => 20200316168 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => INHIBITORS OF IGFBP3 BINDING TO TMEM219 FOR TREATMENT OF INTESTINAL DISEASES [patent_app_type] => utility [patent_app_number] => 16/855992 [patent_app_country] => US [patent_app_date] => 2020-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24510 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16855992 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17749651 [patent_doc_number] => 20220227855 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => COMPOSITIONS AND METHODS FOR TREATMENT OF ANGIOGENESIS RELATED DISEASES [patent_app_type] => utility [patent_app_number] => 17/606173 [patent_app_country] => US [patent_app_date] => 2020-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11444 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17606173 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16221309 [patent_doc_number] => 20200246425 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-06 [patent_title] => Treatments of Metabolic Disorders Using FGF Binding Protein 3 [patent_app_type] => utility [patent_app_number] => 16/840046 [patent_app_country] => US [patent_app_date] => 2020-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15282 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16840046 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17612004 [patent_doc_number] => 20220154283 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => MARKER COMPOSITION FOR DIAGNOSING CANCER OR PREDICTING PROGNOSIS ON BASIS OF EXOSOME OVEREXPRESSING TUBA1C PROTEIN [patent_app_type] => utility [patent_app_number] => 17/442012 [patent_app_country] => US [patent_app_date] => 2020-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3454 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17442012 [rel_patent_id] =>[rel_patent_doc_number] =>)